Login to Your Account

Big Pharma Still Hot for mAbs

Autoimmune, CNS Diseases: Top-Dollar Antibodies Deals

By Jennifer Boggs
Managing Editor

Friday, November 11, 2011
Anyone who has followed the biopharma sector over the past decade knows that big pharma's lust for monoclonal antibody technology isn't going away any time soon. But a recent report and webinar by Deloitte Recap LLC, which broke down more than 1,000 deals over the last 10 years, showed some unexpected trends for companies working in the antibody space.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription